Rocco Haase1, Jennifer S Kullmann2, Tjalf Ziemssen3. 1. Center of Clinical Neuroscience, Neurological Clinic, University Clinic Carl Gustav Carus Dresden, TU Dresden, Germany. 2. Genzyme, a Sanofi company, Neu-Isenburg, Germany. 3. Multiple Sklerose Zentrum, Zentrum für klinische Neurowissenschaften, Universitätsklinik Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
Abstract
BACKGROUND: Improved clinical effectiveness and therefore positive modification of multiple sclerosis (MS) with basic therapy can be achieved by long-term regular intake of drugs as prescribed but investigations have shown that a high percentage of patients do not take their medications as prescribed. OBJECTIVES: We assessed the satisfaction and adherence of patients with MS with their current disease-modifying treatment under clinical practice conditions. We compared different facets of satisfaction as well as their internal relationship and identified predictors in an exploratory manner. METHODS: Therapy satisfaction in patients with relapsing-remitting multiple sclerosis (THEPA-MS) was a noninterventional, prospective cross-sectional study performed throughout Germany in 2013 and 2014, and included patients with clinically isolated syndrome or relapsing-remitting MS. We applied a standardized approach to document satisfaction and adherence by patient-reported outcomes (Treatment Satisfaction Questionnaire for Medication) as well as by physician ratings. RESULTS: Of 3312 patients with a mean age of 43.7 years, 73.3% were women and the mean level of disability according to the Expanded Disability Status Scale was 2.29; 13.3% did not receive any medication at the time of documentation, 21.3% received interferon β1a intramuscularly, 20.7% had interferon β1a subcutaneously, 17.0% had interferon β1b subcutaneously and 23.7% had glatiramer acetate. Adherence rates varied between 60% (lifetime) and 96.5% (current medication). Differences between current medications were found for side effects and convenience scores but not for effectiveness, satisfaction and adherence. Higher global satisfaction and effectiveness were associated with fewer relapses, longer duration of medication, lower disability score and the absence of several side effects. CONCLUSION: In a connected model of patient satisfaction, effectiveness, side effects, convenience and adherence, patients' individual needs and concerns have to be addressed. Most differences were found with respect to side effects and convenience of treatment. Therefore, an improvement in these two domains seems to be the most promising proximate approach to elevate adherence levels.
BACKGROUND: Improved clinical effectiveness and therefore positive modification of multiple sclerosis (MS) with basic therapy can be achieved by long-term regular intake of drugs as prescribed but investigations have shown that a high percentage of patients do not take their medications as prescribed. OBJECTIVES: We assessed the satisfaction and adherence of patients with MS with their current disease-modifying treatment under clinical practice conditions. We compared different facets of satisfaction as well as their internal relationship and identified predictors in an exploratory manner. METHODS: Therapy satisfaction in patients with relapsing-remitting multiple sclerosis (THEPA-MS) was a noninterventional, prospective cross-sectional study performed throughout Germany in 2013 and 2014, and included patients with clinically isolated syndrome or relapsing-remitting MS. We applied a standardized approach to document satisfaction and adherence by patient-reported outcomes (Treatment Satisfaction Questionnaire for Medication) as well as by physician ratings. RESULTS: Of 3312 patients with a mean age of 43.7 years, 73.3% were women and the mean level of disability according to the Expanded Disability Status Scale was 2.29; 13.3% did not receive any medication at the time of documentation, 21.3% received interferon β1a intramuscularly, 20.7% had interferon β1a subcutaneously, 17.0% had interferon β1b subcutaneously and 23.7% had glatiramer acetate. Adherence rates varied between 60% (lifetime) and 96.5% (current medication). Differences between current medications were found for side effects and convenience scores but not for effectiveness, satisfaction and adherence. Higher global satisfaction and effectiveness were associated with fewer relapses, longer duration of medication, lower disability score and the absence of several side effects. CONCLUSION: In a connected model of patient satisfaction, effectiveness, side effects, convenience and adherence, patients' individual needs and concerns have to be addressed. Most differences were found with respect to side effects and convenience of treatment. Therefore, an improvement in these two domains seems to be the most promising proximate approach to elevate adherence levels.
Entities:
Keywords:
convenience; multiple sclerosis; patient adherence; patient satisfaction; patient-centred outcomes research; quality of life; side effects; treatment effectiveness
Authors: Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman Journal: J Neurol Date: 2009-04-27 Impact factor: 4.849
Authors: Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley Journal: Clin Drug Investig Date: 2010 Impact factor: 2.859
Authors: Jonathan Calkwood; Bruce Cree; Heidi Crayton; Daniel Kantor; Brian Steingo; Luigi Barbato; Ron Hashmonay; Neetu Agashivala; Kevin McCague; Nadia Tenenbaum; Keith Edwards Journal: BMC Neurol Date: 2014-11-26 Impact factor: 2.474
Authors: Karam I Turk-Adawi; Neil B Oldridge; Sergey S Tarima; William B Stason; Donald S Shepard Journal: J Am Heart Assoc Date: 2013-10-21 Impact factor: 5.501
Authors: Ishan Hirji; Shaloo Gupta; Amir Goren; Diana R Chirovsky; Alyson B Moadel; Eduardo Olavarria; Timothy W Victor; Catherine C Davis Journal: Health Qual Life Outcomes Date: 2013-10-08 Impact factor: 3.186
Authors: Todd A Hardy; John Parratt; Heidi Beadnall; Stefan Blum; Richard Macdonell; Roy G Beran; Neil Shuey; Andrew Lee; William Carroll; Cameron Shaw; Richard Worrell; Jana Moody; Mamdouh Sedhom; Michael Barnett; Steve Vucic Journal: BMJ Neurol Open Date: 2022-07-04
Authors: Jonathan Alsop; Jennie Medin; Christian Cornelissen; Stefan Viktor Vormfelde; Tjalf Ziemssen Journal: PLoS One Date: 2017-05-05 Impact factor: 3.240
Authors: Gesa E A Pust; Benthe Untiedt; Jennifer Randerath; Anna Barabasch; Sascha Köpke; Anne C Rahn; Hilke Hansen; Christoph Heesen Journal: Int J MS Care Date: 2020-01-22
Authors: Jiwon Oh; Bryan Walker; Gavin Giovannoni; Dominic Jack; Fernando Dangond; Axel Nolting; Julie Aldridge; Lori A Lebson; Thomas P Leist Journal: Mult Scler J Exp Transl Clin Date: 2021-07-13